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Hematopoietic stem cell transplantation is used to treat patients with hematologic malignancies. 
Blood stem cells for transplantation are obtained from donor bone marrow, peripheral blood, or 
umbilical cord blood (CB). Before receiving a transplant, patients first must undergo myeloablative 
conditioning regimens to remove diseased bone marrow and to create an immunosuppressive 
environment that allows engraftment of donor stem cells and reconstitution of a normal blood 
system. Donors and recipients are matched for human leukocyte antigen (HLA) alleles to reduce 
graft-versus-host disease (GVHD), which occurs when donor cells mount an immune response 
against recipient cells. HLA mismatches are better tolerated using CB transplant (CBT) compared to 
other sources of stem cells. For patients who lack a donor HLA match or who cannot tolerate 
traditional transplant regimens, CBT offers an effective therapy for advanced or high-risk 
hematologic malignancies. 
To obtain enough stem cells for engraftment, patients receive CB from two donors sequentially. 
Previous studies by Dr. Colleen Delaney and colleagues from the Clinical Research Division 
determined that double-unit CBT had a similar leukemia-free survival (53%, 95% confidence interval 
41-59%) to other sources of adult stem cells, including HLA-matched donors (related or unrelated), 
or HLA-mismatched unrelated donors (Brunstein et al., 2010). However, there is a delay in 
hematopoietic recovery and a higher risk of non-relapse mortality for double-unit CBT compared to 
other sources of blood stem cells. 
For older patients and those with comorbidities, reduced-intensity conditioning (RIC) regimens 
promote engraftment through immunosuppression, but result in less tissue damage, inflammation, 
and lower rates of GVHD than traditional myeloablative regimens. Optimal conditions for RIC in CBT 
have not been established. Antithymocyte globulin (ATG), an infusion of rabbit antibodies against T-
cells, has been used in some RIC CBT regimens to reduce acute GVHD. However, ATG can result 
in delayed reconstitution of T-cells, an increased risk of post-transplant EBV-driven 
lymphoproliferative disorder, an increased risk of viral infections, and decreased graft-versus-tumor 
effect. Drs. Fabiana Ostronoff, Filippo Milano, Colleen Delaney and colleagues in the Clinical 
Research Division evaluated a RIC regimen without ATG for CBT in advanced and high-risk 
hematologic malignancies where no donor match was available. The primary goal of their study was 
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to estimate the probability of overall survival at one year for a RIC without ATG, to establish a 
benchmark to compare as an estimate for future trials. 
Between February 2006 and January 2011, 30 patients with various high-risk advanced hematologic 
malignancies underwent double-unit CBT with a RIC regimen without ATG. Prior to CBT, patients 
were treated for four days with fludarabine, a purine analog chemotherapeutic agent; a single dose 
of cyclophosphamide, an alkylating agent; and total body irradiation at doses of 200-450 cGy, 
depending on risk of graft failure and previous treatments. Twenty-seven of 30 patients recovered 
their neutrophil count after transplant between six to 40 days, median 17 days. Of the three patients 
who did not reach engraftment, two died from multi-organ failure and one died of hemorrhagic 
meningitis. Of note, two of these patients were considered a high-risk of graft failure. 
Compared to other RIC CBT regimens that include ATG, the incidence of acute GVHD was similar in 
this RIC CBT regimen without ATG; 13 of 28 patients had a grade II GVHD. Probability of chronic 
GVHD was estimated at 2 years at 18%, although follow up was limited in some patients and they 
are still at risk of developing chronic GVHD. Even though one or two HLA alleles were mismatched 
for the two CB units, GVHD incidence was similar to that seen with HLA-matched bone marrow or 
peripheral blood transplants. There were 11 cases of non-relapse mortality, with estimated 
probability of 29% at one year, which is similar to non-relapse mortality in RIC CBT performed with 
ATG included in the treatment regimen. Eight patients relapsed after transplant. Of those who 
relapsed, only two survived at the last follow-up. 13 patients had survived the RIC CBT at the last 
study follow-up (range of 114-1303 days post transplant). From this data, the estimated overall 
survival was 53% at 1 year, which matched previous studies examining double-unit CBT 
(Brunstein et al., 2010). 
The results of this small study suggest that removing ATG from a RIC regimen does not affect graft 
failure or GVHD incidence for double-unit CBT. Larger studies with longer follow-up are needed to 
confirm these findings. Importantly, the RIC regimen also needs to be optimized to minimize graft 
failure, improve hematopoietic recovery and reduce non-relapse mortality to improve the efficacy of 
CBT.  
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